#Actavis agrees to buy #Warner Chilcott for $8.5B in deal that likely puts Actavis out of reach of would-be predators #Valeant or #Mylan
#Elan on a deal-making tear with plans to buy two private firms, spin-off an experimental drug, repurchase shares and issue debt – phew!
LONDON, May 16 (Reuters) – AstraZeneca has enrolled
the first patient into a final-stage clinical trial of a new
drug for a rare type of leukaemia as the group’s new CEO
delivers on a promise to accelerate its oncology programmes.
Britain’s second-biggest drugmaker said on Thursday the
Phase III clinical trial would test moxetumomab pasudotox in
patients with hairy cell leukaemia who have not responded to or
have relapsed after standard therapy.